With regard to the final remark concerning the Commission's proposal to retain the medicine's initial name in the event of extending authorisation, I support keeping the initial name, since frequently changing the names of medicines may confuse patients who need, in any case, to see a doctor before receiving any treatment, and the doctor will be up to date with the medicine's new therapeutic indications.
Mis puudutab viimast märkust seoses komisjoni ettepanekuga jätta olemasoleva müügiloa korral alles ravimi esialgne nimi, siis toetan ma esialgse nime allesjätmist, kuna tihti võib ravimite nimede muutmine ajada segadusse patsiente, kes peavad iga kord enne ravi saamist arstiga konsulteerima, ning arst on kursis ravimi uute raviomadustega.